Shares of Adamis Pharmaceuticals Co. (NASDAQ:ADMP) have earned an average rating of “Buy” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $7.88.
Several research analysts have weighed in on ADMP shares. Maxim Group set a $5.00 price objective on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, February 14th. Raymond James set a $7.00 price objective on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, February 23rd. B. Riley reissued a “buy” rating on shares of Adamis Pharmaceuticals in a report on Wednesday, March 14th. Zacks Investment Research lowered shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, March 16th. Finally, HC Wainwright started coverage on shares of Adamis Pharmaceuticals in a report on Monday, April 23rd. They set a “buy” rating and a $7.00 price objective for the company.
A number of hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP acquired a new position in Adamis Pharmaceuticals during the 1st quarter worth $244,000. Northern Trust Corp grew its holdings in Adamis Pharmaceuticals by 50.7% during the 1st quarter. Northern Trust Corp now owns 139,536 shares of the specialty pharmaceutical company’s stock worth $489,000 after acquiring an additional 46,924 shares in the last quarter. B. Riley Financial Inc. acquired a new position in Adamis Pharmaceuticals during the 4th quarter worth $1,022,000. Virtu Financial LLC acquired a new position in shares of Adamis Pharmaceuticals in the 4th quarter valued at about $442,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Adamis Pharmaceuticals by 1,050.3% in the 4th quarter. Wells Fargo & Company MN now owns 28,182 shares of the specialty pharmaceutical company’s stock valued at $124,000 after buying an additional 25,732 shares during the period. 11.50% of the stock is owned by institutional investors.
ADMP opened at $4.35 on Friday. The firm has a market cap of $136.06 million, a P/E ratio of -4.83 and a beta of 0.36. Adamis Pharmaceuticals has a twelve month low of $4.05 and a twelve month high of $4.40. The company has a quick ratio of 1.57, a current ratio of 1.88 and a debt-to-equity ratio of 0.07.
Adamis Pharmaceuticals (NASDAQ:ADMP) last announced its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.06). The company had revenue of $3.18 million for the quarter, compared to analyst estimates of $3.34 million. Adamis Pharmaceuticals had a negative return on equity of 71.68% and a negative net margin of 207.24%. equities analysts forecast that Adamis Pharmaceuticals will post -0.74 earnings per share for the current year.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.